Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab + cisplatin + docetaxel in first-line advanced NSCLC with biomarker-based assessment
2008-008387-27Phase 2Active
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Start
- Nov 2009
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab, cisplatin and docetaxel in non-small cell lung cancer (NSCLC), sponsored by Gruppo Oncologico Italiano di Ricerca Clinica. Primary endpoint: Response rate. Started Nov 2009; status: active.
02
Drugs
cetuximabcisplatindocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2008-008387-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-008387-27.